OncoMatch/Clinical Trials/NCT06552260
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Is NCT06552260 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Troriluzole for glioblastoma.
Treatment: Troriluzole — This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: IDH2 wild-type
Disease stage
Required: Stage WHO GRADE 4 (WHO 2021)
Grade: 4 (WHO)
WHO Grade 4, and variants including gliosarcoma as per WHO 2021 criteria; Confirmed measurable disease per RANO 2.0 for GBM
Prior therapy
Must have received: radiation therapy
Prior treatment with radiotherapy with or without chemotherapy.
Cannot have received: troriluzole (troriluzole)
Prior treatment with troriluzole or riluzole
Cannot have received: riluzole (riluzole)
Prior treatment with troriluzole or riluzole
Lab requirements
Blood counts
ANC ≥ 1,500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 9 g/dL
Kidney function
Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min
Liver function
Total bilirubin ≤ 2 × ULN (unless Gilbert's Syndrome, then < 5 mg/dL); AST/ALT ≤ 1.5 × ULN
Cardiac function
NYHA Functional Classification 2B or better
Laboratory values at the Screening Visit: ANC count < 1,500/mm3; Platelets <100,000/mm3; Hemoglobin < 9 g/dL; Total bilirubin > 2 × ULN (unless Gilbert's Syndrome, then < 5 mg/dL); AST > 1.5 x ULN; ALT > 1.5 x ULN; Serum creatinine > 1.5 mg/dL or creatinine clearance < 60 mL/min. Cardiac: NYHA Functional Classification 2B or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06552260 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior troriluzole, riluzole disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage WHO GRADE 4 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages